DUROLANE®
hyaluronic acid, stabilized single injection

Help your osteoarthritis (OA) patients feel better for longer with DUROLANE:

This hyaluronic acid (HA) injection—with a unique combination of patented NASHA® technology and high molecular weight—makes it possible.[1-6]

Discover the lasting benefits of DUROLANE:

Manufactured with **patented NASHA® technology** to cross link and entangle HA to resist degradation and prolong joint residence time.*[2,3,7]

Has the **highest reported molecular weight** — 10^{15} kDa — of any HA indicated for the treatment of OA.†[8,9]

Has the **longest reported total joint residence time** compared to other leading HA preparations.*[3,7,10-12]

Longer duration of action, combined with joint cartilage protection, makes **OA symptom relief and delay to total joint replacement** possible for your OA patients.*[4,13-17]

Scan to discover the **DUROLANE difference** by requesting an evaluation sample.‡

*Preclinical residence time has not been correlated with the duration of clinical effect.
†Based on theoretical calculations.
‡Terms and conditions apply.

The One
The Only*

DUROLANE®
hyaluronic acid, stabilized single injection

A one-injection HA treatment designed to deliver powerful, long-lasting knee OA pain relief.[2,4,14,15,18-20]

Scan to learn how DUROLANE can make the difference for your OA patients. Or visit DUROLANE.com.

*DUROLANE is one of the available single-injection hyaluronic acid products for symptomatic treatment of OA.

References: 1. Phillips M, Vannabouathong C, Devji T, et al. Differentiating factors of intra-articular injectables have a meaningful impact on knee osteoarthritis outcomes: a network meta-analysis. *Knee Surg Sports Traumatol Arthrosc*. 2020;28(9):3031-9. doi:10.1007/s00167-019-05763-1. **2.** Ågerup B, Berg P, Åkermark C. Non-animal stabilized hyaluronic acid: a new formulation for the treatment of osteoarthritis. *BioDrugs*. 2005;19(1):23-30. doi:10.2165/00063030-200519010-00003. **3.** Lindqvist U, Tolmachev V, Kairemo K, Åström G, Jonsson E, Lundqvist H. Elimination of stabilised hyaluronan from the knee joint in healthy men. *Clin Pharmacokinet*. 2002;41(8):603-13. doi:10.2165/00003088-200241080-0000. **4.** Carney G, Harrison A, Fitzpatrick J. Long-term outcome measures of repeated non-animal stabilized hyaluronic acid (Durolane) injections in osteoarthritis: a 6-year cohort study with 623 consecutive patients. *Open Access Rheumatol*. 2021;13:285-92. doi:10.2147/OARRR.S331562. **5.** Lesley J, Hascall VC, Tammi M, Hyman R. Hyaluronan binding by cell surface CD44*. *J Biol Chem*.2000;275(35):26967-75. doi:10.1074/jbc.M002527200. **6.** Altman R, Lim S, Steen RG, Dasa V. Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: evidence from a large U.S. health claims database. *PLoS One*. 2015;10(12):e0145776. doi:10.1371/journal.pone.0145776. **7.** Edsman K, Hjelm R, Lärkner H, et al. Intra-articular duration of Durolane™after single injection into the rabbit knee. *Cartilage*. 2011;2(4)384-8. doi:10.1177/1947603511400184. **8.** Nicholls M, Manjoo A, Shaw P, Niazi F, Rosen J. Rheological properties of commercially available hyaluronic acid products in the United States for the treatment of osteoarthritis knee pain. *Clin Med Insights Arthritis Musculoskelet Disord*. 2018;11:1179544117751622. doi:10.1177/1179544117751622. **9.** Bioventus LLC. Q-Med Molecular Weight of DUROLANE. Data on file, RPT-001314. June 2021. **10.** Larsen NE, Dursema HD, Pollak CT, Skrabut EM. Clearance kinetics of a hylan-based viscosupplement after intra-articular and intravenous administration in animal models. *J Biomed Mater Res B Appl Biomater*. 2012;100(2):457-62. doi:10.1002/jbm.b.31971. **11.** Sakamoto T. Biological fate of sodium hyaluronate (SPH) (1) Studies on distribution, metabolism and excretion of 14C-SPHin rabbits after intraarticular administration. *Pharmacometrics*. 1984;28(2):375-87. **12.** Edsman K, Melin H, Nässtrom J. A study of the ability of Durolane™ to withstand degradation by free radicals while maintaining its viscoelastic properties. Poster presented at: 55th Annual Meeting of the Orthopaedic Research Society; February 22-25, 2009; Las Vegas, NV. Poster 1149. **13.** Bioventus LLC. Supporting quantity of global patients treated with a single DUROLANE injection. Data on file, RPT-001056. **14.** Leighton R, Åkermark C, Therrien R, et al. NASHA hyaluronic acid vs. methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. *Osteoarthritis Cartilage*.2014;22(1):17-25. doi:10.1016/j.joca.2013.10.009. **15.** Zhang H, Zhang K, Zhang X, et al. Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz. *Arthritis Res Ther*.2015;17(1):51. doi:10.1186/s13075-015-0557-x. **16.** Jurado MR, Fidalgo AE, Villar VR, Medina JM, Lopez BS. Factors related with the time to surgery in waiting-list patients for knee prostheses. *Reumatol Clin*. 2013;9(3):148-55. doi:10.1016/j.reuma.2012.09.003. **17.** Plaas A, Li J, Riesco J, Das R, Sandy JD, Harrison A. Intraarticular injection of hyaluronan prevents cartilage erosion, periarticular fibrosis and mechanical allodynia and normalizes stance time in murine knee osteoarthritis. *Arthritis Res Ther*. 2011;13:R46. doi:10.1186/ar3286. **18.** McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. *J Arthritis*. 2013;2(1):1000108. doi:10.4172/2167-7921.1000108. **19.** DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2019. **20.** Krocker D, Matziolis G, Tuischer J, et al. Reduction of arthrosis associated knee pain through a single intra-articular injection of synthetic hyaluronic acid. *Z Rheumatol*. 2006;65(4):327-31. doi:10.1007/s00393-006-0063-2.

Summary of Indications for Use:
Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes. DUROLANE is also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure. There are no known contraindications. DUROLANE should not be used in patients who have infections or skin disease at the injection site. DUROLANE has not been tested in children or pregnant or lactating women. Risks can include transient pain, swelling and/or stiffness at the injection site.

Full prescribing information can be found in product labeling, or at DUROLANE.com.

bioventus®
Innovations For Active Healing